Head to head
MariTide against Semaglutide
Once monthly against once weekly, and an unusual mechanistic disagreement underneath: MariTide blocks the GIP receptor that tirzepatide activates. The dosing interval is the part a person feels and the receptor question is the part the field has not settled.
Column A
MariTideMaridebart Cafraglutide (MariTide, AMG 133)
Amgen's monthly-dosed obesity drug that pairs GLP-1 activation with GIP receptor blockade, reaching around 20% weight loss in Phase 2.
Column B
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Side by side, on the facts we can check
| Attribute | MariTide | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational (Phase 3) | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | Weeks (monthly dosing) | ~7 days |
| Molecular weight | About 145 kDa: the maridebart antibody component is 144,765 Da (KEGG) and carries two conjugated GLP-1 peptide analogs | 4,113.6 Da |
| Mechanism | Activates the GLP-1 receptor while blocking the GIP receptor, delivered as a long-acting peptide-antibody conjugate for monthly dosing. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Human studies cited | 2 | 5 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between MariTide and Semaglutide?
MariTide: Amgen's monthly-dosed obesity drug that pairs GLP-1 activation with GIP receptor blockade, reaching around 20% weight loss in Phase 2. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, MariTide or Semaglutide?
This database does not grade compounds. It counts what was run in people: 2 of the 2 studies cited on the MariTide profile were human work, against 5 of 5 for Semaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are MariTide and Semaglutide FDA-approved?
MariTide: Investigational (Phase 3). Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Related posts
Blog articles that cover MariTide or Semaglutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.